FDA Approval Update for TREXALL (Methotrexate Sodium) by Barr
The FDA has granted an Abbreviated New Drug Application (ANDA) approval for TREXALL, a methotrexate sodium product by Barr.
Asset / Drug
Drug and asset intelligence for TREXALL with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Chemotherapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.